Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease.
With growing drug resistance the epidemic remains and will require significant attention and …

The US Food and Drug Administration (FDA) on 28 December 2012 granted accelerated
approval to Johnson and Johnson's drug bedaquiline to treat resistant tuberculosis (TB) …

The World Health Organization (WHO) estimated that 490 000 cases of multidrug-resistant
(MDR) tuberculosis (TB)(defined as TB caused by Mycobacterium tuberculosis strains …

ABSTRACT A regimen comprised of bedaquiline (BDQ, or B), pretomanid, and linezolid
(BPaL) is the first oral 6-month regimen approved by the US Food and Drug Administration …

Tuberculosis is an airborne infectious disease treated with combination therapeutic
regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining …

Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

ABSTRACT PA-824 is a novel nitroimidazo-oxazine under evaluation as an antituberculosis
agent. A dose-ranging randomized study was conducted to evaluate the safety, tolerability …

ABSTRACT PA-824 is in phase II clinical testing to treat tuberculosis. At a dose of 100 mg/kg
of body weight, it has demonstrated bactericidal activity during the initial and continuation …